Immunocore
IMCR
104 hedge funds and large institutions have $1.73B invested in Immunocore in 2022 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 26 reducing their positions, and 13 closing their positions.
138% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 13
68% more call options, than puts
Call options by funds: $10.3M | Put options by funds: $6.12M
39% more capital invested
Capital invested by funds: $1.25B → $1.73B (+$480M)
38% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 26
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
21% more funds holding
Funds holding: 86 → 104 (+18)
6.47% more ownership
Funds ownership: 60.31% → 66.78% (+6.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$83.2M |
| 2 |
RI
RTW Investments
New York
|
+$62.4M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$34.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.4M |
| 5 |
BlackRock
New York
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$52.1M |
| 2 |
CAC
Cowen and Company
New York
|
-$34.1M |
| 3 |
First Manhattan
New York
|
-$10.2M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$9.72M |
| 5 |
RG
Rathbones Group
Liverpool,
United Kingdom
|
-$8.92M |
IMCR Hedge Fund Activity: Q4 2022 in Review
104 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Immunocore (IMCR) for Q4 2022, worth a combined $1.73B — up 39% from $1.25B a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new IMCR positions and 13 closed out — a net gain of 18 holders — while 36 added to existing stakes and 26 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $83.2M. The largest seller was Avidity Partners Management, cutting an estimated $52.1M.
- 104 institutional investors held Immunocore (IMCR) as of Q4 2022, up from 86 in Q3 2022.
- Funds reported $1.73B of Immunocore stock for Q4 2022, up 39% quarter-over-quarter.
- 31 funds opened new Immunocore positions in Q4 2022 and 13 closed out, a net change of +18 holders.
- The largest Immunocore buyer in Q4 2022 was Wellington Management Group, an estimated $83.2M added.
- The largest Immunocore seller in Q4 2022 was Avidity Partners Management, an estimated $52.1M sold.
Based on aggregated 13F filings for Q4 2022.